Evaluating Off-label Use of Direct Oral Anticoagulants (DOACs) in Hypercoagulable States
Completed
- Conditions
- Hypercoagulable States
- Registration Number
- NCT04565977
- Lead Sponsor
- Methodist Health System
- Brief Summary
Retrospective, cohort study chart review in patients with hypercoagulable states.
- Detailed Description
* Retrospective, cohort study chart review in patients at Methodist Health System
* Data will be pulled on all patients with hypercoagulable states identified by ICD-9/ICD-10 codes from January 1st, 2015 to December 31st, 2019
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
- Patients ≥ 18 year-old
- Patients with diagnosis of hypercoagulable state identified by ICD-9/ICD-10 codes
- Patients who were prescribed DOACs or VKA for primary or secondary prevention of thrombosis
Exclusion Criteria
- Patients with FDA-approved indications of oral anticoagulants including atrial fibrillation or treatment/prevention of thrombotic events unrelated to specified hypercoagulable states
- Patients with incomplete electronic medical records
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rates of hemorrhagic events during the study period Jan 1,2015 - Dec 31st, 2019 Rates of hemorrhagic events during the study period
Rates of thrombotic events during the study period Jan 1,2015 - Dec 31st, 2019 Rates of thrombotic events during the study period
- Secondary Outcome Measures
Name Time Method Rates of DOAC prescribing for thrombosis prevention in hypercoagulable states Jan 1,2015 - Dec 31st, 2019 Rates of DOAC prescribing for thrombosis prevention in hypercoagulable states
Trial Locations
- Locations (1)
Methodist Dallas Medical Center
🇺🇸Dallas, Texas, United States
Methodist Dallas Medical Center🇺🇸Dallas, Texas, United States